Results of a randomized phase II study comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) (ELDORANDO-AIO-KHT-0115)

Gruenwald V, Graeven U, Ivanyi P, Dietz A, Hahn D, Hackenberg S, Kasper S, Fietkau R, Moulin JC, Pink D, Schaaf M, Klinghammer K (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Annals of Oncology Elsevier

Publisher: ELSEVIER

City/Town: AMSTERDAM

Pages Range: S807-S808

Conference Proceedings Title: ANNALS OF ONCOLOGY

DOI: 10.1016/j.annonc.2021.08.1322

Authors with CRIS profile

Rainer Fietkau Lehrstuhl für Strahlentherapie

Involved external institutions

Universitätsklinikum Essen DE Germany (DE) Kliniken Maria Hilf GmbH DE Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School DE Germany (DE) Universität Leipzig DE Germany (DE) Klinikum Stuttgart DE Germany (DE) Universitätsklinikum Würzburg DE Germany (DE) Ortenau Klinikum DE Germany (DE) HELIOS Kliniken DE Germany (DE) The Institute of Cancer Research (ICR) GB United Kingdom (GB) Charité - Universitätsmedizin Berlin DE Germany (DE)

How to cite

APA:

Gruenwald, V., Graeven, U., Ivanyi, P., Dietz, A., Hahn, D., Hackenberg, S.,... Klinghammer, K. (2021). Results of a randomized phase II study comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) (ELDORANDO-AIO-KHT-0115). In ANNALS OF ONCOLOGY (pp. S807-S808). AMSTERDAM: ELSEVIER.

MLA:

Gruenwald, V., et al. "Results of a randomized phase II study comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) (ELDORANDO-AIO-KHT-0115)." Proceedings of the ANNALS OF ONCOLOGY AMSTERDAM: ELSEVIER, 2021. S807-S808.

BibTeX: Download